Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group-Reference-Cited by-同舟云学术

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group

Published:2003-06 Issue:6 Volume:14 Page:833-842
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Martin M.,Villar A.,Sole-Calvo A.,Gonzalez R.,Massuti B.,Lizon J.,Camps C.,Carrato A.,Casado A.,Candel M.T.,Albanell J.,Aranda J.,Munarriz B.,Campbell J.,Diaz-Rubio E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/14/6/833/365803/mdg260.pdf

Reference13 articles.

1. Combination chemotherapy as an adjuvant treatment in operable breast cancer;Bonadonna;N Engl J Med,1976

2. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up;Bonadonna;N Engl J Med,1995

3. Polychemotherapy for early breast cancer: An overview of the randomized trials;Early Breast Cancer Trialists’ Collaborative Group;Lancet,1998

4. Reporting results of cancer treatment;Miller;Cancer,1981

5. A randomized trial comparing CMF with FAC in breast cancer adjuvant treatment Toxicity analysis;Martin;Ann Oncol,1994

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Writers, readers, and erasers RNA modifications and drug resistance in cancer;Molecular Cancer;2024-08-30

2. Curcumin synergistically augments the chemotherapeutic activity of Doxorubicin in prostate cancer cells;Interdisciplinary Medical Journal;2024-04-29

3. Simultaneous Delivery of Doxorubicin and EZH2‐Targeting siRNA by Vortex Magnetic Nanorods Synergistically Improved Anti‐Tumor Efficacy in Triple‐Negative Breast Cancer;Small;2023-06-27

4. Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis;Pharmaceuticals;2023-03-30

5. eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model;Cells;2022-12-15